MA46337A - Composé de pyridine - Google Patents

Composé de pyridine

Info

Publication number
MA46337A
MA46337A MA046337A MA46337A MA46337A MA 46337 A MA46337 A MA 46337A MA 046337 A MA046337 A MA 046337A MA 46337 A MA46337 A MA 46337A MA 46337 A MA46337 A MA 46337A
Authority
MA
Morocco
Prior art keywords
pyridine compound
pharmaceutically acceptable
acceptable salt
relates
compound
Prior art date
Application number
MA046337A
Other languages
English (en)
Other versions
MA46337B1 (fr
Inventor
Hiroaki Inagaki
Hideaki Kageji
Yasuyuki Kaneta
Kiyoshi Nakayama
Hidenori Namiki
Yoshihiro Shibata
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MA46337A publication Critical patent/MA46337A/fr
Publication of MA46337B1 publication Critical patent/MA46337B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne un composé ayant une action inhibitrice de la kinase ret ou un sel pharmaceutiquement acceptable de celui-ci, utile dans le traitement de maladies telles que le cancer. En particulier, l'invention concerne un composé représenté par la formule générale (i) suivante telle que définie dans la description : (i) ou un sel pharmaceutiquement acceptable de celui-ci.
MA46337A 2016-09-29 2017-09-28 Composé de pyridine MA46337B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (fr) 2016-09-29 2017-09-28 Composé de pyridine

Publications (2)

Publication Number Publication Date
MA46337A true MA46337A (fr) 2019-08-07
MA46337B1 MA46337B1 (fr) 2021-04-30

Family

ID=60020249

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46337A MA46337B1 (fr) 2016-09-29 2017-09-28 Composé de pyridine
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Country Status (32)

Country Link
US (2) US10851092B2 (fr)
EP (2) EP3828178A1 (fr)
JP (2) JP2018052878A (fr)
KR (1) KR102520543B1 (fr)
CN (2) CN113788824A (fr)
AU (2) AU2017335242C1 (fr)
BR (1) BR112019006047A2 (fr)
CA (1) CA3035860A1 (fr)
CL (1) CL2019000844A1 (fr)
CO (1) CO2019004034A2 (fr)
CY (1) CY1123988T1 (fr)
DK (1) DK3519398T3 (fr)
EA (1) EA037103B1 (fr)
EC (1) ECSP19030134A (fr)
ES (1) ES2868748T3 (fr)
HR (1) HRP20210447T1 (fr)
HU (1) HUE054824T2 (fr)
IL (1) IL265630B (fr)
LT (1) LT3519398T (fr)
MA (2) MA46337B1 (fr)
MD (1) MD3519398T2 (fr)
MX (1) MX2019003747A (fr)
PE (1) PE20190805A1 (fr)
PH (1) PH12019500480A1 (fr)
PL (1) PL3519398T3 (fr)
PT (1) PT3519398T (fr)
RS (1) RS61640B1 (fr)
SG (1) SG11201901937WA (fr)
SI (1) SI3519398T1 (fr)
UA (1) UA123964C2 (fr)
WO (1) WO2018060714A1 (fr)
ZA (1) ZA201902232B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3371171T3 (fi) 2015-11-02 2024-01-10 Blueprint Medicines Corp Ret:n estäjiä
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
US20210100795A1 (en) 2018-04-03 2021-04-08 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
EP3942045A1 (fr) 2019-03-21 2022-01-26 Onxeo Molécule dbait associée à un inhibiteur de kinase pour le traitement du cancer
EP4054579A1 (fr) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
WO2021100677A1 (fr) * 2019-11-18 2021-05-27 中外製薬株式会社 Association médicamenteuse
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN115210226B (zh) * 2020-02-20 2024-01-09 广州白云山医药集团股份有限公司白云山制药总厂 喹啉类化合物
WO2021164741A1 (fr) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 Composé de bisamide de phényle
WO2022238706A1 (fr) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Inhibiteur de ret pour le traitement du cancer médullaire de la thyroïde à altération de ret ou du cancer du poumon non à petites cellules à altération de ret
WO2023239422A2 (fr) 2021-10-22 2023-12-14 University Of Houston System Méthodes et compositions pour traiter une lésion inflammatoire chronique, une métaplasie, une dysplasie et des cancers des tissus épithéliaux
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
EP1994023A1 (fr) 2006-03-02 2008-11-26 AstraZeneca AB Dérivés de la quinazoline
JP2009528336A (ja) 2006-03-02 2009-08-06 アストラゼネカ アクチボラグ キノリン誘導体
WO2007113548A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de naphtyridine
WO2007113565A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de la naphtyridine comme agents anti-cancéreux
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
ES2459722T3 (es) * 2009-02-27 2014-05-12 Teijin Pharma Limited Procedimiento para producir un derivado heterocíclico sustituido con fenilo mediante acoplamiento usando un catalizador de metal de transición
EP2467137A1 (fr) 2009-08-19 2012-06-27 Ambit Biosciences Corporation Composés biaryles et procédés d utilisation de ceux-ci
RU2561055C2 (ru) 2009-08-25 2015-08-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
WO2011133728A2 (fr) 2010-04-23 2011-10-27 Kineta, Inc. Composés antiviraux
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
CA2878895A1 (fr) 2012-07-13 2014-01-16 Indiana University Research & Technology Corporation Composes utilisables en vue du traitement de l'amyotrophie spinale
AU2014229233B2 (en) * 2013-03-15 2016-08-11 Glaxosmithkline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors
RU2016111675A (ru) * 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
EP3135667A4 (fr) * 2014-04-24 2017-11-01 Mitsubishi Tanabe Pharma Corporation Nouveaux dérivés de 2-amino-pyridine et 2-amino-pyrimidine et leur utilisation médicinale
CR20170094A (es) * 2014-09-10 2017-05-08 Glaxosmithkline Ip Dev Ltd Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret)
SG11201701694QA (en) * 2014-09-10 2017-04-27 Glaxosmithkline Ip Dev Ltd Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
CN107427506A (zh) 2014-10-14 2017-12-01 拉霍拉敏感及免疫学研究所 低分子量蛋白酪氨酸磷酸酶的抑制剂及其用途
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
US10202365B2 (en) * 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
AU2016291676B2 (en) 2015-07-16 2020-04-30 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
JP2019534871A (ja) 2019-12-05
CN113788824A (zh) 2021-12-14
IL265630A (en) 2019-05-30
RS61640B1 (sr) 2021-04-29
IL265630B (en) 2021-10-31
MA54910A (fr) 2022-04-13
CL2019000844A1 (es) 2019-06-07
PL3519398T3 (pl) 2021-06-28
LT3519398T (lt) 2021-05-10
EA037103B1 (ru) 2021-02-05
UA123964C2 (uk) 2021-06-30
EA201990833A1 (ru) 2019-10-31
SG11201901937WA (en) 2019-04-29
AU2017335242B2 (en) 2021-08-19
EP3519398A1 (fr) 2019-08-07
HRP20210447T1 (hr) 2021-07-23
MD3519398T2 (ro) 2021-05-31
AU2021261899A1 (en) 2021-12-02
JP7098609B2 (ja) 2022-07-11
KR20190086442A (ko) 2019-07-22
HUE054824T2 (hu) 2021-10-28
CA3035860A1 (fr) 2018-04-05
US20210163464A1 (en) 2021-06-03
AU2017335242C1 (en) 2021-12-09
PT3519398T (pt) 2021-03-24
ES2868748T3 (es) 2021-10-21
ECSP19030134A (es) 2019-08-30
WO2018060714A1 (fr) 2018-04-05
SI3519398T1 (sl) 2021-07-30
CY1123988T1 (el) 2022-05-27
EP3828178A1 (fr) 2021-06-02
US10851092B2 (en) 2020-12-01
EP3519398B1 (fr) 2021-02-24
BR112019006047A2 (pt) 2019-06-25
CO2019004034A2 (es) 2019-07-10
AU2017335242A1 (en) 2019-05-02
MX2019003747A (es) 2019-09-19
US20200039974A1 (en) 2020-02-06
DK3519398T3 (da) 2021-03-29
ZA201902232B (en) 2022-12-21
CN110036007A (zh) 2019-07-19
PH12019500480A1 (en) 2019-08-05
MA46337B1 (fr) 2021-04-30
CN110036007B (zh) 2021-10-15
JP2018052878A (ja) 2018-04-05
PE20190805A1 (es) 2019-06-10
KR102520543B1 (ko) 2023-04-10

Similar Documents

Publication Publication Date Title
MA46337B1 (fr) Composé de pyridine
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA35861B1 (fr) Inhibiteur de la kinase régulant les signaux de l'apoptose
MA38454B1 (fr) Inhibiteurs de protéines kinases
EA201890473A1 (ru) Гетероарильные производные в качестве ингибиторов parp
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
MA52948B1 (fr) Composés
EA201991884A2 (ru) Ингибиторы g12c kras
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MA39983B1 (fr) Dérivés de carboxamide
MA39152B1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA50093B1 (fr) Composé pentacyclique
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA40605B1 (fr) Composé pyrazolothiazole et médicament
MA43231B1 (fr) Bloqueur des canaux sodiques
MX2021007258A (es) Composiciones de esparsentan amorfas.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MA38991A1 (fr) Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt
MA39432A (fr) Dérivé de tetrahydropyrrolo[3,4-d][1,3]thiazine en tant qu'inhibiteur de bace
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7